awmsg logo



abatacept (Orencia®)


Reference No. 2985

Publication date:
18/11/2016


Appraisal information

abatacept (Orencia®) 250 mg powder for concentrate for solution for infusion
abatacept (Orencia®) 125 mg solution for injection


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 17/11/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, abatacept (Orencia®) cannot be endorsed for use within NHS Wales in combination with methotrexate for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
Statement of Advice (SOA)
Download